Global Generics Market Bolstered by Value-Added ‘Supergenerics’

LONDON--(BUSINESS WIRE)-- The generic drugs market is expanding at a robust rate, attributed to the increased focus on cost cutting measures in the world’s medical and healthcare settings, according to a new report available from As patent expiries loom, many big pharmaceutical companies are becoming increasingly concerned over the competition from low cost generic alternatives, which are certain to erode their market share.

Generic Drugs: The Global Market - Focus on Asia

To combat the post-patent cliff generic threat – a key factor influencing the growth of the generics market – many of the big pharma companies at risk have adopted several defensive strategies, for example filing judicial challenges, and incorporating their own generic units.

Other factors influencing the generic market expansion include the development of supergenerics, which not only offer a low cost alternative to branded pharmaceutical products, but offer additional value. Supergenerics are ‘tweaked’ versions of an original drug, and may differ in formulation or method of delivery. In some instances, supergeneric drugs may need a new drug application prior to being granted FDA approval.

Biogenerics (also known as biosimilars) are also a potentially lucrative market for generic businesses with the capabilities or financing to support the activity, as many first generation biopharmaceuticals are reaching their own patent expiry dates.

Included within the generic drugs research report are profiles of the top ten generics companies, with discussion over their generics, products, financial situation and future. These are: Actavis, Apotex Inc., Dr. Reddy's Laboratories, Ltd., Hospira, Inc., Mylan Inc., Par Pharmaceutical, Inc., Ranbaxy Laboratories, Ltd., Sandoz International GmbH, Teva Pharmaceutical Industries, Ltd. and Watson Pharmaceuticals, Inc. Additional profiles of international generic companies are also included.

Published in September 2011, the 161 page study examines the generics market for the period 2011-2016. The global generics marketplace is discussed, with specific reference to the Asian region and the countries of Japan, India and China. The report discusses the regional pharmaceuticals and generics markets of each of these countries, as well as referencing demographic and regulatory factors of relevance.

Report Details:


Companies & Markets
Mike King
Press Office
[email protected]
London (UK): +44 (0) 203 086 8600

KEYWORDS:   United Kingdom  Europe

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Other Health